Drugs Made In America Acquisition II Corp. Ordinary Shares

DMII | NASDAQ

$10.20

$0.00 (0.00%)

At close: Oct 30, 2026, 3:59 PM ET

$10.19

-$0.01 (-0.10%)

After-hours: Oct 30, 2026, 4:02 PM ET

TTM Period Ending	Q2 2026 Jun 30, 2026	Q1 2026 Mar 31, 2026	Q4 2025 Dec 31, 2025	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q3 2024 Sep 30, 2024
Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-1.45M	-1.37M	-1.3M	-252.91K	-139.08K	-101.01K	-41.68K
Interest Income	8.95M	4.44M	n/a	109.36K	n/a	n/a	n/a
Pretax Income	13.02M	8.58M	4.19M	-143.56K	-139.08K	-101.01K	-41.68K
Net Income	13.02M	8.58M	4.19M	-143.56K	-139.08K	-101.01K	-41.68K
Selling & General & Admin	635.24K	561.09K	488.39K	252.91K	139.08K	101.01K	41.68K
Research & Development	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Other Expenses	812.11K	812.11K	812.11K	n/a	n/a	n/a	n/a
Operating Expenses	1.45M	1.37M	1.3M	252.91K	139.08K	101.01K	41.68K
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	1.45M	1.37M	1.3M	252.91K	139.08K	101.01K	41.68K
Income Tax Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Shares Outstanding (Basic)	50M	50M	13.29M	2.72M	33.21M	63.7M	63.7M
Shares Outstanding (Diluted)	50M	50M	13.29M	2.72M	33.21M	63.7M	63.7M
EPS (Basic)	0.30	0.23	0.16	-0.02	0	0	n/a
EPS (Diluted)	0.29	0.22	0.15	-0.02	0	0	n/a
EBITDA	-1.45M	-1.37M	-1.3M	-252.91K	-139.08K	-101.01K	-41.68K
EBIT	-1.45M	-1.37M	-1.3M	-252.91K	-139.08K	-101.01K	-41.68K
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	n/a